Helical Tomotherapy Combined with Capecitabine in the Preoperative Treatment of Locally Advanced Rectal Cancer

Abstract EN

The aim of this study was to evaluate the efficacy of helical tomotherapy plus capecitabine as a preoperative chemoradiotherapy (CRT) in patients with locally advanced rectal cancer (LARC).

Thirty-six LARC patients receiving preoperative CRT were analyzed.

Radiotherapy (RT) consisted of 45 Gy to the regional lymph nodes and simultaneous-integrated boost (SIB) 50.4 Gy to the tumor, 5 days/week for 5 weeks.

Chemotherapy consisted of capecitabine 850 mg/m2, twice daily, during the RT days.

Patients underwent surgery 6–8 weeks after completion of CRT.

Information was collected for patient characteristics, treatment response, and acute and late toxicities.

Grade 3/4 (G3+) toxicities occurred in 11.1% of patients (4/36).

Sphincter preservation rate was 85.2% (23/27).

Five patients (14.3%) achieved pathological complete response.

Tumor, nodal, and ypT0-2N0 downstaging were noted in 60% (21/35), 69.6% (16/23), and 57.1% (20/35).

Tumor regression grade 2~4 was achieved in 28 patients (80%).

After a median follow-up time of 35 months, the most common G3+ late morbidity was ileus and fistula (5.7%, 2/35).

The study showed that capecitabine plus helical tomotherapy with an SIB is feasible in treatment of LARC.

The treatment modality can achieve a very encouraging sphincter preservation rate and a favorable ypT0-2N0 downstaging rate without excessive toxicity.